Home › Funds › Ikarian Capital, LLC › DRUG
Ikarian Capital, LLC position in DRUG
BRIGHT MINDS BIOSCIENCES INC · Health Care
Ikarian Capital, LLC reported holding 88,951 shares of DRUG (BRIGHT MINDS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$4.4M, representing 0.65% of its reported portfolio and ranking #41 among its reported holdings. Ikarian Capital, LLC has disclosed DRUG holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's DRUG position evolved
Ikarian Capital, LLC first disclosed a stake in DRUG in Q4 2024 at 152,211 shares (US$5.5M). The position peaked in Q4 2025 at 159,421 shares, worth US$12.4M. Across 8 filings, Ikarian Capital, LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 88,951 shares valued at US$4.4M. Notable position changes include a 57% trim in Q1 2025 (shares fell 28% over the following quarter), a 76% trim in Q3 2025 (shares rose 29% over the following quarter), a 933% increase in Q4 2025 (shares fell 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 152.21K | $5.48M | New |
| Q1 2025 | 65.43K | $2.36M | Reduce |
| Q2 2025 | 65.43K | $1.71M | Hold |
| Q3 2025 | 15.43K | $936.04K | Reduce |
| Q4 2025 | 159.42K | $12.44M | Add |
| Q1 2026 | 166.65K | $12.16M | Add |
| Q2 2026 | 88.95K | $6.24M | Reduce |
| Q3 2026 | 88.95K | $4.43M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DRUG and 13F data
DRUG (BRIGHT MINDS BIOSCIENCES INC) is a Health Care company. 60 other funds we track also report a position in DRUG — the largest reported positions include Cormorant Asset Management, LP (US$39.9M), Vestal Point Capital, LP (US$27.2M), BRAIDWELL LP (US$24.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DRUG
- Cormorant Asset Management, LP 800.00K sh · $39.86M · Q3 2026
- Vestal Point Capital, LP 545.00K sh · $27.15M · Q3 2026
- BRAIDWELL LP 483.82K sh · $24.10M · Q3 2026
- Vivo Capital, LLC 417.88K sh · $20.82M · Q3 2026
- MPM BioImpact LLC 195.67K sh · $9.75M · Q3 2026
- GREAT POINT PARTNERS LLC 109.60K sh · $5.46M · Q3 2026
- B Group, Inc. 95.00K sh · $4.73M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 93.15K sh · $4.64M · Q3 2026
- Sio Capital Management, LLC 75.15K sh · $3.74M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 48.05K sh · $2.39M · Q3 2026
- Artia Global Partners LP 38.41K sh · $1.91M · Q3 2026
- KVP Capital Advisors, LP 31.81K sh · $1.58M · Q3 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held DRUG?
Ikarian Capital, LLC has disclosed DRUG holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Ikarian Capital, LLC's current position in DRUG?
As of Q3 2026, Ikarian Capital, LLC holds 88.95K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $4.43M, representing 0.65% of its reported portfolio and ranking #41.
Has Ikarian Capital, LLC been buying or selling DRUG?
In the latest 13F filing (Q3 2026), Ikarian Capital, LLC held unchanged its position in DRUG. The position peaked in Q4 2025 at 159.42K shares.
Which other funds hold DRUG?
Other major institutional holders of DRUG include Cormorant Asset Management, LP, Vestal Point Capital, LP, BRAIDWELL LP, among 60 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.